BioCryst Pharm (BCRX) volatility increases as shares rally 13%
BioCryst Pharmaceuticals (Nasdaq: BCRX) is recently up $1.35 to $11.45. BCRX received an initial order for 10,000 courses of intravenous peramivir with a value of $22.5M under a newly issued contract with the department of health. BCRX November call option implied volatility is at 103, puts are at 133, December calls are at 88, puts at 125; verses its 26-week average of 118. BCRX call option volume of 15,741 contracts compares to put volume of 3,662 contracts according to Track Data. Puts are more expensive than calls because BCRX is difficult to borrow. Paul Foster
You May Also Be Interested In
- Nokia (NOK) Volatility Up as Shares Bounce Off Multi-Year Lows; Loses Top Mobile Spot to Samsung
- Wal-Mart (WMT) volatility flat at 19 into Q1 revenue of $112.3B
- CBOE Volatility Index (VIX) down 0.86 to 23.63; S&P 500 recently up 0.18%
Create E-mail Alert Related Categories
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
